


TG 100801 Hydrochloride

Cat. No.:	HY-10187
CAS No.:	1018069-81-2
Molecular Formula:	C ₃₃ H ₃₁ Cl ₂ N ₅ O ₃
Molecular Weight:	616.54
Target:	VEGFR; FGFR; PDGFR; Src
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro

DMSO : 5 mg/mL (8.11 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	1.6220 mL	8.1098 mL	16.2195 mL	
5 mM	0.3244 mL	1.6220 mL	3.2439 mL	
10 mM	---	---	---	

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

IC₅₀ & Target

VEGFR1 2 nM (IC ₅₀)	VEGFR2 7 nM (IC ₅₀)	FGFR1 2 nM (IC ₅₀)	FGFR2 16 nM (IC ₅₀)
PDGFRβ 13 nM (IC ₅₀)			

In Vitro

TG 100801 is a topically administered prodrug delivered as an eye drop that is readily converted to the active TG 100572 in the eye. TG 100572 is shown to inhibit hRMVEC cell proliferation, with an IC₅₀ of 610±72 nM^[1]. TG 100801 is formed by derivitization of a phenolic moiety in TG100572 to yield an ester. It displays excellent balance of stability (physical and chemical) with hydrolysis rate. On its own, TG 100801 does not display meaningful anti-kinase activity, as the ester group blocks key interactions with kinase active sites, however exposure to esterases (abundant in mammalian tissues) rapidly liberates active TG100572. TG 100572 shows sub-nanomolar activity against the Src family as well as RTK such as VEGFR1 and

R2, FGFR1 and R2, and PDGFR β . TG 100572 inhibits vascular endothelial cell proliferation (ED₅₀=610±71 nM) and blocks VEGF-induced phosphorylation of extracellular signal-regulated kinase. TG 100572 induces apoptosis in rapidly proliferating, but not quiescent, endothelial cell cultures^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TG 100801 exhibits excellent ocular pharmacokinetics and poor systemic circulation and shows good efficacy in the laser induced choroidal neovascularization model. A concentration of 23.4 μ M (C_{max}) of TG 100572 is reached in 30 min (T_{max})=0.5 h) in the choroid and the sclera. However, the levels of TG 100572 in the retina are relatively low. The half-life of TG 100572 in ocular tissues is very short; hence, the compound is administered topically minimum t.i.d. to maintain appropriate drug levels in the eye. The maximum concentration one can achieve in formulations using TG 100572 is 0.7% w/v^[1]. TG 100801 nor TG100572 are detectable in plasma following topical delivery of TG 100801, and adverse safety signals (such as weight loss) are not observed even with prolonged dosing schedules. Topical TG 100801 significantly suppresses laser-induced choroidal neovascularization in mice, and reduces fluorescein leakage from the vasculature and retinal thickening measured by optical coherence tomography in a rat model or retinal vein occlusion. Systemic delivery of TG 100572 in a murine model of laser-induced choroidal neovascularization (CNV) causes significant suppression of CNV, but with an associated weight loss suggestive of systemic toxicity^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[2]

Rats: Long Evans rats are dosed topically in both eyes with 10 μ L of TG 100801 (as a 0.3, 0.6 or 1% solution) or vehicle. A total of 5 topical applications are delivered per eye over a three day period: dosing is performed one hour prior to and six hours after laser-induced thrombosis on Day 1, twice on Day 2, and once the morning of Day 3. One hour after the final topical application, retinal edema is assessed by one of two means^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Science. 2017 Dec 1;358(6367):eaan4368.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Palanki MS, et al. Development of prodrug 4-chloro-3-(5-methyl-3-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. J Med Chem. 2008 Mar 27;51(6):1546-59.

[2]. Doukas, John, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. Journal of Cellular Physiology (2008), 216(1), 29-37.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA